Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP2 | P08253 | 12/20 | 0.57 |
| ▸ | MMP9 | P14780 | 6/20 | 0.57 |
| ▸ | MMP8 | P22894 | 6/20 | 0.57 |
| ▸ | MMP1 | P03956 | 11/20 | 0.55 |
| ▸ | MMP3 | P08254 | 9/20 | 0.55 |
| ▸ | PDE4A | P27815 | 4/20 | 0.43 |
| ▸ | PDE4B | Q07343 | 4/20 | 0.43 |
| ▸ | PDE4C | Q08493 | 4/20 | 0.43 |
| ▸ | PDE4D | Q08499 | 4/20 | 0.43 |
| ▸ | MMP13 | P45452 | 6/20 | 0.42 |
| ▸ | PPARG | P37231 | 1/20 | 0.39 |
| ▸ | PPARA | Q07869 | 1/20 | 0.39 |
| ▸ | CNR2 | P34972 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7073432 | 0.89 | MMP2 (0.60) | MMP2MMP9MMP8MMP1MMP3 | |
| SCHEMBL8002828 | 0.88 | MMP2 (0.57) | MMP2MMP9MMP8MMP1MMP3 | |
| SCHEMBL7075404 | 0.86 | MMP2 (0.67) | MMP2MMP9MMP8MMP1MMP3 | |
| SCHEMBL7079276 | 0.84 | MMP2 (0.52) | MMP2MMP9MMP8MMP1MMP3 | |
| SCHEMBL7074188 | 0.82 | MMP2 (0.52) | MMP2MMP9MMP8MMP1MMP3 | |
| SCHEMBL7297379 | 0.78 | MMP13 (0.53) | MMP2MMP9MMP8MMP1MMP3 | |
| SCHEMBL7534733 | 0.76 | MMP2 (0.58) | MMP2MMP9MMP8MMP1MMP3 | |
| SCHEMBL7077710 | 0.75 | MMP2 (0.70) | MMP2MMP9MMP8MMP1MMP3 | |
| SCHEMBL8013554 | 0.75 | MMP2 (0.74) | MMP2MMP9MMP8MMP1MMP3 | |
| SCHEMBL7422537 | 0.74 | MMP2 (0.56) | MMP2MMP9MMP8MMP1MMP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030207889-A1 | Hydroxamic and carboxylic acid derivatives having MMP and TNF inhibitory activity | OWEN DAVID ALAN (GB) | 2003-11-06 | — | — | US | disclosed |
| US-6566384-B1 | For therapy of cancer, inflammation and inflammatory diseases, tissue degeneration, periodontal disease, ophthalmological disease, dermatological disorders, fever, cardiovascular effects, haemorrhage, coagulation and acute phase response | DARWIN DISCOVERY LTD. (GB) | 2003-05-20 | — | — | US | disclosed |
| US-6118001-A | ANTICANCER AGENT; ANTIARTHRITIC AGENT | DARWIN DISCOVERY, LTD. (GB) | 2000-09-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030207889-A1 | Hydroxamic and carboxylic acid derivatives having MMP and TNF inhibitory activity | MMP13, MMP2, MMP9 | MMP2 2/4885MMP9 3/4885MMP8 18/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.